<DOC>
	<DOCNO>NCT02142608</DOCNO>
	<brief_summary>Pilot study evaluate sensitivity specificity BR55 target prostate cancer nodule Gleason score great equal 7 .</brief_summary>
	<brief_title>A Pilot Trial Using BR55 Ultrasound Contrast Agent Assessment Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male , age 5070 year old Increased PSA level &gt; 4 ng/mL Known prostate cancer Scheduled prostatectomy earlier 3 day later 30 day follow BR55 administration ( exception training case requirement applicable ) Provides write informed consent willing comply protocol requirement Documented acute prostatitis urinary tract infection Known suffer stable angina pectoris and/or proven coronary disease , symptoms suspicious coronary disease History clinically unstable cardiac condition include class III/IV cardiac failure rightto leave shunt Severe cardiac rhythm disorder within last 7 day Severe pulmonary hypertension uncontrolled systemic hypertension respiratory distress syndrome Received prostate biopsy procedure within 30 day admission study Determined investigator clinically unsuitable study Participating concurrent clinical trial participate another clinical trial investigational compound within past 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Ultrasound Imaging</keyword>
</DOC>